Jackson Tai - Eli Lilly Independent Director

LLY Stock  USD 778.18  3.28  0.42%   

Director

Mr. Jackson Peter Tai is an Independent Director of the Company. Mr. Tai is a former CEO with extensive experience in international business and finance, and is an audit committee financial expert. He has deep expertise in the AsiaPacific region, a key growth market for Lilly. He also has broad corporate governance experience from his service on public company boards in the U.S., Europe, and Asia. since 2013.
Age 71
Tenure 11 years
Professional MarksMBA
Address Lilly Corporate Center, Indianapolis, IN, United States, 46285
Phone317 276 2000
Webhttps://www.lilly.com

Eli Lilly Management Efficiency

The company has Return on Asset of 0.1188 % which means that on every $100 spent on assets, it made $0.1188 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.4844 %, implying that it generated $0.4844 on every 100 dollars invested. Eli Lilly's management efficiency ratios could be used to measure how well Eli Lilly manages its routine affairs as well as how well it operates its assets and liabilities. Return On Assets is likely to rise to 0.12 in 2024, whereas Return On Capital Employed is likely to drop 0.25 in 2024. At this time, Eli Lilly's Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 40.2 B in 2024, whereas Non Currrent Assets Other are likely to drop slightly above 2.9 B in 2024.
The company has 25.23 B in debt with debt to equity (D/E) ratio of 1.58, which is OK given its current industry classification. Eli Lilly And has a current ratio of 1.11, demonstrating that it may not be capable to disburse its financial commitments when the payables are due. Debt can assist Eli Lilly until it has trouble settling it off, either with new capital or with free cash flow. So, Eli Lilly's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Eli Lilly And sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Eli to invest in growth at high rates of return. When we think about Eli Lilly's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

DIRECTOR Age

Stephen ConnellyEquillium
42
Dennis AusielloSeres Therapeutics
72
Kenneth BateMadrigal Pharmaceuticals
67
Arturo Testa23Andme Holding Co
37
Heidi FieldsAgilent Technologies
60
Roy Blom23Andme Holding Co
65
Paul FriedmanMadrigal Pharmaceuticals
75
Frederick CravesMadrigal Pharmaceuticals
72
Richard LevyMadrigal Pharmaceuticals
60
John FisherEquillium
60
James DalyMadrigal Pharmaceuticals
N/A
Gregory BeharSeres Therapeutics
48
Kurt GravesSeres Therapeutics
50
Donald KufeMadrigal Pharmaceuticals
69
Johannes Tiden23Andme Holding Co
34
Robert WilsonMadrigal Pharmaceuticals
75
Anders Forseback23Andme Holding Co
N/A
Daniel PodolskyAgilent Technologies
67
Ettore Artioli23Andme Holding Co
N/A
Salvatore Falco23Andme Holding Co
46
AnnChristine Hvittfeldt23Andme Holding Co
49
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana. Eli Lilly operates under Drug ManufacturersGeneral classification in the United States and is traded on New York Stock Exchange. It employs 35000 people. Eli Lilly And (LLY) is traded on New York Stock Exchange in USA. It is located in Lilly Corporate Center, Indianapolis, IN, United States, 46285 and employs 43,000 people. Eli Lilly is listed under Pharmaceuticals category by Fama And French industry classification.

Management Performance

Eli Lilly And Leadership Team

Elected by the shareholders, the Eli Lilly's board of directors comprises two types of representatives: Eli Lilly inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Eli. The board's role is to monitor Eli Lilly's management team and ensure that shareholders' interests are well served. Eli Lilly's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Eli Lilly's outside directors are responsible for providing unbiased perspectives on the board's policies.
Ralph Alvarez, Independent Director
Jamere Jackson, Independent Director
Johna Norton, Senior Vice President - Global Quality
Juan Luciano, Lead Independent Director
J Fyrwald, Independent Director
Alfonso Zulueta, Senior Vice President and President - Emerging Markets business
Anne White, Senior Vice President and Presidentident - Lilly Oncology
Melissa Barnes, Senior Vice President - Enterprise Risk Management and Chief Ethics and Compliance Officer
Patrik Jonsson, Senior Vice President, Chief Customer Officer, President - Lilly Immunology, Lilly USA
Karen Walker, Independent Director
Ilya Yuffa, Senior Vice President and President of Lilly Bio-Medicines
Enrique Conterno, Senior Vice President and President - Lilly Diabetes and President - Lilly USA
Raul Alvarez, Independent Director
Marschall Runge, Independent Director
Anat JD, General VP
Myles ONeill, Senior Vice President and President - Manufacturing Operations
David Ricks, Senior Vice President and Presidentident - Lilly Bio-Medicines
Daniel Skovronsky, Senior Vice President, Chief Scientific and Medical Officer, President - Lilly Research Laboratories
Edgardo Hernandez, Senior Vice President and Presidentident - Manufacturing Operations
Donald Zakrowski, Chief Finance
Carolyn Bertozzi, Independent Director
Erik Fyrwald, Independent Director
Franklyn Prendergast, Independent Director
Ellen Marram, Lead Independent Director
Kathi Seifert, Independent Director
Eric Dozier, Executive Diversity
Joshua Smiley, Chief Financial Officer, Senior Vice President
Anat Hakim, Senior Vice President, General Counsel, Secretary
Fionnuala Walsh, Senior Vice President - Global Quality
Alonzo Weems, Senior Vice President - Enterprise Risk Management, Chief Ethics and Compliance Officer
Gabrielle Sulzberger, Independent Director
Anat Ashkenazi, Chief Financial Officer, Senior Vice President
Jeffrey Simmons, Senior Vice President and President - Elanco Animal Health
John Lechleiter, Chairman, CEO and Pres
Karen Horn, Independent Director
Leigh Pusey, Senior Vice President - Corporate Affairs and Communications
Darren Carroll, Senior Vice President - Corporate Business Development
William Kaelin, Independent Director
Jacob Naarden, Senior Vice President, Chief Executive Officer - Loxo Oncology at Lilly, President - Lilly Oncology
Christi Shaw, Senior Vice President and President - Lilly Bio-Medicines
Barton Peterson, Senior Vice President - Corporate Affairs and Communications
Derica Rice, CFO, Executive VP of Global Services, Member of Operations Committee and Member of Policy and Strategy Committee
Kimberly Johnson, Independent Director
Michael Harrington, Executive Vice President, General Counsel
David Hoover, Independent Director
Maria Crowe, President - Manufacturing Operations
Diogo Rau, Senior Vice President Chief Information and Digital Officer
Jan Lundberg, Executive VP of Science and Technology and President of Lilly Research Laboratories
Aarti Shah, Senior Vice President - Chief Information and Digital Officer
Susan Mahony, Senior Vice President and President - Lilly Oncology
Jackson Tai, Independent Director
Michael Eskew, Independent Director
Martin MIBS, VP Projects
Katherine Baicker, Independent Director
Stephen Fry, Senior Vice President - Human Resources and Diversity
Michael Mason, Senior Vice President and President Lilly Diabetes

Eli Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Eli Lilly a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Eli Lilly And offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Eli Lilly's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Eli Lilly And Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Eli Lilly And Stock:
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Eli Lilly And. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis.
You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.

Complementary Tools for Eli Stock analysis

When running Eli Lilly's price analysis, check to measure Eli Lilly's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Eli Lilly is operating at the current time. Most of Eli Lilly's value examination focuses on studying past and present price action to predict the probability of Eli Lilly's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Eli Lilly's price. Additionally, you may evaluate how the addition of Eli Lilly to your portfolios can decrease your overall portfolio volatility.
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios
Is Eli Lilly's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Eli Lilly. If investors know Eli will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Eli Lilly listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
0.13
Dividend Share
4.52
Earnings Share
5.81
Revenue Per Share
37.908
Quarterly Revenue Growth
0.281
The market value of Eli Lilly And is measured differently than its book value, which is the value of Eli that is recorded on the company's balance sheet. Investors also form their own opinion of Eli Lilly's value that differs from its market value or its book value, called intrinsic value, which is Eli Lilly's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Eli Lilly's market value can be influenced by many factors that don't directly affect Eli Lilly's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Eli Lilly's value and its price as these two are different measures arrived at by different means. Investors typically determine if Eli Lilly is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Eli Lilly's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.